Literature DB >> 6439271

Bronchodilator-mediated relaxation of normal and ovalbumin-sensitized guinea-pig airways: lack of correlation with lung adenylate cyclase activation.

J F Burka, M H Saad.   

Abstract

Isoprenaline, vasoactive intestinal peptide (VIP), prostaglandin E2 (PGE2) and forskolin caused a dose-dependent relaxation of normal and ovalbumin-sensitized guinea-pig tracheal spirals and lung parenchymal strips in vitro. There was no difference in magnitude of relaxation or sensitivity to these relaxants between normal and sensitized tissues. The rank order of potency (concentration of each drug at which 50% of the maximum is obtained) for these relaxants on both trachea and parenchyma was VIP greater than isoprenaline greater than PGE2 greater than forskolin, although the parenchyma was more sensitive than the trachea. The rank order of efficacy of the drugs used in relaxing both the trachea and lung parenchyma was isoprenaline (10 microM) greater than forskolin (30 microM) greater than VIP (0.1 microM) greater than PGE2 (10 microM). PGE2 at concentrations greater than 1 microM sometimes contracted the lung strip. Pretreatment with indomethacin (8.5 microM), a cyclo-oxygenase inhibitor, reduced the resting tone of tracheal spirals, but did not significantly affect the tone of lung strips. Indomethacin-pretreatment did not affect drug-induced relaxations of either normal or sensitized tracheal spirals. However, both normal and sensitized indomethacin-pretreated lung strips relaxed significantly less (P less than 0.05) to isoprenaline, PGE2 and forskolin. Indomethacin-pretreatment did not affect sensitivity of normal and sensitized trachea or parenchyma to the relaxant drugs. All the relaxant drugs used stimulated adenylate cyclase activity in normal or sensitized lung parenchyma membrane preparations. The rank order of efficacy (maximal activation) was forskolin greater than isoprenaline = VIP greater than PGE2. There was no difference in response between normal and sensitized lungs. Adenylate cyclase activity of normal lung was stimulated as follows: forskolin (100 microM), 500.0 +/- 50.0%; isoprenaline (100 microM), 186.0 +/- 29.0%; VIP (10 microM), 213.0 +/- 19.0% and PGE2 (100 microM), 155.0 +/- 23.0% of basal activity. Similar values were obtained for sensitized lung parenchyma. Indomethacin-pretreatment did not significantly affect normal or sensitized lung adenylate cyclase stimulation by isoprenaline, VIP, forskolin or PGE2. It was concluded that: Immunological sensitization to ovalbumin does not induce hypoactivity of relaxant drug receptors and/or the adenylate cyclase system of the airway tissues of the guinea-pig. (b) There is an apparent lack of correlation between tissue relaxation in vitro and adenylate cyclase activity since the rank order of the efficacy of a range of relaxants was different for the two effects and furthermore indomethacin-treatment of airway tissues yielded differential results.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439271      PMCID: PMC1987096          DOI: 10.1111/j.1476-5381.1984.tb16218.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Arachidonic acid metabolism and SRS-A.

Authors:  P J Piper; J R Tippins; H R Morris; G W Taylor
Journal:  Agents Actions Suppl       Date:  1979

2.  THE SPIRALLY CUT TRACHEAL STRIP PREPARATION.

Authors:  J W CONSTANTINE
Journal:  J Pharm Pharmacol       Date:  1965-06       Impact factor: 3.765

3.  Prostaglandins and the lung.

Authors:  A L Hyman; E W Spannhake; P J Kadowitz
Journal:  Am Rev Respir Dis       Date:  1978-01

4.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

5.  Evidence for lipoxygenase pathway involvement in allergic tracheal contraction.

Authors:  J F Burka; N A Paterson
Journal:  Prostaglandins       Date:  1980-04

Review 6.  Bronchial hyperreactivity.

Authors:  H A Boushey; M J Holtzman; J R Sheller; J A Nadel
Journal:  Am Rev Respir Dis       Date:  1980-02

7.  Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle.

Authors:  W R Kukovetz; S Holzmann; A Wurm; G Pöch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

8.  Depressed cyclic AMP levels in airways smooth muscle from asthmatic dogs.

Authors:  G A Rinard; A R Rubinfeld; L L Brunton; S E Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

9.  The lymphocyte beta-adrenoceptor in normal subjects and patients with bronchial asthma: the effect of different forms of treatment on receptor function.

Authors:  M E Conolly; J K Greenacre
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  The isolated lung strip and single open tracheal ring: a convenient combination for characterizing Schultz Dale anaphylactic contractions in the peripheral and central airways of the guinea-pig.

Authors:  K M Lulich; J M Papadimitriou; J W Paterson
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 Nov-Dec       Impact factor: 2.557

View more
  4 in total

Review 1.  Pharmacological studies of pulmonary anaphylaxis in vitro: a review.

Authors:  P O Ogunbiyi; P Eyre
Journal:  Agents Actions       Date:  1985-12

2.  Responses to histamine and selective H2-receptor agonists in lung parenchymal strips from normal and sensitized guinea-pigs.

Authors:  J Cortijo; C Sanz; M Perpiñá; J L Ortiz; J D Orón; J Esplugues; E J Morcillo
Journal:  Agents Actions       Date:  1989-08

3.  A study of the H2-receptor for histamine stimulating adenylate cyclase in homogenates of guinea-pig lung parenchyma.

Authors:  J C Foreman; D B Norris; T J Rising; S E Webber
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

4.  A study of the histamine H2-receptor mediating relaxation of the parenchymal lung strip preparation of the guinea-pig.

Authors:  J C Foreman; T J Rising; S E Webber
Journal:  Br J Pharmacol       Date:  1985-10       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.